全文获取类型
收费全文 | 427篇 |
免费 | 22篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 12篇 |
妇产科学 | 8篇 |
基础医学 | 41篇 |
口腔科学 | 2篇 |
临床医学 | 51篇 |
内科学 | 82篇 |
皮肤病学 | 4篇 |
神经病学 | 24篇 |
特种医学 | 12篇 |
外科学 | 66篇 |
综合类 | 15篇 |
一般理论 | 2篇 |
预防医学 | 16篇 |
眼科学 | 26篇 |
药学 | 35篇 |
中国医学 | 4篇 |
肿瘤学 | 44篇 |
出版年
2023年 | 7篇 |
2022年 | 5篇 |
2021年 | 15篇 |
2020年 | 12篇 |
2019年 | 16篇 |
2018年 | 27篇 |
2017年 | 10篇 |
2016年 | 10篇 |
2015年 | 16篇 |
2014年 | 24篇 |
2013年 | 27篇 |
2012年 | 38篇 |
2011年 | 34篇 |
2010年 | 26篇 |
2009年 | 17篇 |
2008年 | 15篇 |
2007年 | 24篇 |
2006年 | 26篇 |
2005年 | 18篇 |
2004年 | 6篇 |
2003年 | 7篇 |
2002年 | 5篇 |
2001年 | 4篇 |
2000年 | 11篇 |
1999年 | 6篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1971年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有453条查询结果,搜索用时 0 毫秒
451.
Jeremiah Wasserlauf MD MS Kelly Vogel BS Cailin Whisler MPH Emelia Benjamin MD ScM Robert Helm MD Daniel A. Steinhaus MD Omair Yousuf MD Rod S. Passman MD MSCE 《Journal of cardiovascular electrophysiology》2023,34(5):1103-1107
Introduction
The Apple watch (AW) irregular rhythm notification (IRN) feature uses photoplethysmography to identify prolonged episodes of irregular rhythm suggestive of atrial fibrillation (AF). IRN is FDA cleared for those with no previous history of AF, however, these devices are increasingly being used for AF management. The objective of the present study was to determine the accuracy of the IRN in subjects with a previous diagnosis of nonpermanent AF.Methods
Subjects with a history of nonpermanent AF and either an insertable cardiac monitor (ICM) or cardiac implanted electronic device (CIED) with <5% ventricular pacing were fitted with an AW Series 5 for 6 months. AF episodes were compared between the ICM/CIED and IRN. The primary endpoints were sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the IRN by subject for AF ≥1 h. Secondary endpoints were sensitivity and PPV by AF episode ≥1 h. Analysis was limited to a maximum of 10 ICM/CIED episodes per subject and included only those AF episodes occurring during active AW use confirmed by activity data.Results
Thirty participants were enrolled. Mean age was 65.4 ± 12.2 years and 40% were female. There were 10 ICMs and 20 CIEDs. Eleven subjects had AF on ICM/CIED while the AW was worn, of whom 8 were detected by IRN. There were no false positive IRN detections by subject (“by subject” 72% sensitivity, 100% specificity, 100% PPV, and 90% NPV). Five subjects had AF only when the AW was not worn. There were a total of 70 AF episodes on ICM/CIED, 35 of which occurred while the AW was being worn. Of these, 21 were detected by IRN with 1 false positive (“by episode” sensitivity = 60.0%, PPV = 95.5%).Conclusion
In a population with known AF, the AW IRN had a low rate of false positive detections and high specificity. Sensitivity for detection by subject and by AF episode was lower. The current IRN algorithm appears accurate for AF screening as currently cleared, but increased sensitivity and wear times would be necessary for disease management. 相似文献452.
Victoria G. Hall Victor H. Ferreira Matthew Ierullo Terrance Ku Tina Marinelli Beata Majchrzak-Kita Anila Yousuf Vathany Kulasingam Atul Humar Deepali Kumar 《American journal of transplantation》2021,21(12):3980-3989
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody testing, surrogate neutralization assays, and T cell assays. Patients were immunized with two doses of vaccine and immunogenicity assessed after each dose using the above tests. CD4+ and CD8+ T cell responses were assessed in a subset using flow-cytometry. A total of 127 patients were enrolled of which 110 provided serum at all time points. A positive anti-RBD antibody was seen in 5.0% after one dose and 34.5% after two doses. Neutralizing antibody was present in 26.9%. Of note, 28.5% of patients with anti-RBD did not have neutralizing antibody. T cell responses in a sub-cohort of 48 patients showed a positive CD4+ T cell response in 47.9%. Of note, in this sub-cohort, 46.2% of patients with a negative anti-RBD, still had a positive CD4+ T cell response. The vaccine was safe and well-tolerated. In summary, immunogenicity of mRNA-1273 COVID-19 vaccine was modest, but a subset of patients still develop neutralizing antibody and CD4+T- cell responses. Importantly polyfunctional CD4+T cell responses were observed in a significant portion who were antibody negative, further highlighting the importance of vaccination in this patient population. IRB Statement: This study was approved by the University Health Network Research Ethics Board (CAPCR ID 20–6069). 相似文献
453.
Cathy J. Bradley PhD K. Robin Yabroff PhD S. Yousuf Zafar MD Ya-Chen Tina Shih PhD 《CA: a cancer journal for clinicians》2021,71(2):100-106
Cancer treatment is associated with financial hardship for many patients and families. Screening for financial hardship and referrals to appropriate resources for mitigation are not currently part of most clinical practices. In fact, discussions regarding the cost of treatment occur infrequently in clinical practice. As the cost of cancer treatment continues to rise, the need to mitigate adverse consequences of financial hardship grows more urgent. The introduction of quality measurement and reporting has been successful in establishing standards of care, reducing disparities in receipt of care, and improving other aspects of cancer care outcomes within and across providers. The authors propose the development and adoption of financial hardship screening and management as an additional quality metric for oncology practices. They suggest relevant stakeholders, conveners, and approaches for developing, testing, and implementing a screening and management tool and advocate for endorsement by organizations such as the National Quality Forum and professional societies for oncology care clinicians. The confluence of increasingly high-cost care and widening disparities in ability to pay because of underinsurance and lack of health insurance coverage makes a strong argument to take steps to mitigate the financial consequences of cancer. 相似文献